[The effect of cilazapril on left ventricular function and myocardial perfusion in patients with essential hypertension (hypertensive disease) stage II].
22 patients (mean age 45.08 +/- 1.38 years) with essential hypertension stage II were entered in a placebo-controlled blind trial of cilazapril, angiotensin-converting enzyme. A complex of clinical-instrumental tests comprised dipidamol test, bicycle ergometry, 199Tl myocardial scintigraphy, echo-CG. A 3-month course of cilazapril reduced myocardial hypoperfusion in 15 patients, improved left ventricular relaxation: Anti-ischemia effect of the drug was also evident.
D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002908:Chronic Disease; D017315:Cilazapril / Q000008:administration & dosage / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects*
D000959:Antihypertensive Agents; D017315:Cilazapril
Vliianie tsilazaprila na funktsiiu levogo zheludochka i perfuziiu miokarda u bol'nykh s éssentsial'noĭ gipertonieĭ (gipertonicheskoĭ bolezn'iu) II stadii.